| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.063 | 0.2 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.06 | 0.2 |
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.065 | 0.2 |